Tirzepatideyinoveli ye-agonist ephindwe kabini ye-GIP kunye ne-GLP-1 receptors, evunyiweyo kulawulo lwe-glycemic kubantu abadala abanesifo seswekile sohlobo lwe-2 kunye nolawulo lobunzima bexesha elide kubantu abane-body mass index (BMI) ≥30 kg/m², okanye ≥27 kg/m² ubuncinane obunye obunxulumene nobunzima.
Kwisifo seswekile, yehlisa zombini ukutya kunye ne-postprandial glucose ngokulibazisa ukukhutshwa kwesisu, ukuphucula i-insulin exhomekeke kwi-glucose secretion, kunye nokucinezela ukukhutshwa kweglucagon, kunye nomngcipheko ophantsi we-hypoglycemia xa kuthelekiswa ne-insulin secretagogues. Kulawulo lokutyeba, izenzo zayo ezimbini ezisembindini kunye nepheripheral zinciphisa umdla kunye nokwandisa inkcitho yamandla. Izilingo zeklinikhi zibonise ukuba iiveki ze-52-72 zonyango zinokufikelela kwi-avareji yokunciphisa ubunzima bomzimba we-15% -20%, ehamba kunye nokuphucula kwi-circumference circumference, i-blood pressure, kunye ne-triglycerides.
Ezona ziganeko zibi zixhaphakileyo zibuthathaka ukuya kwiimpawu zesisu esiphakathi, ezidla ngokwenzeka kwiiveki ezimbalwa zokuqala kwaye zithotywe kukunyuka kwedosi kancinci. Ukuqaliswa kweklinikhi kunconywa phantsi kovavanyo lwe-endocrinologist okanye ingcali yokulawula ubunzima, ngokubeka iliso okuqhubekayo kwe-glucose, ubunzima bomzimba kunye nomsebenzi wezintso. Ngokubanzi, i-tirzepatide inikeza ukhetho olusekelwe kubungqina, olukhuselekileyo, kunye noluzinzileyo lwezonyango kwizigulane ezifuna zombini i-glycemic kunye nokulawula ubunzima.
Ixesha lokuposa: Aug-27-2025